ArticleAlimentary pharmacology & therapeutics2022
Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom.
Article in Alimentary pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Cost-of-Illness of Irritable Bowel Syndrome: A Systematic Review.Journal of gastroenterology and hepatology · 2026Pooled it
- Evaluation of the effectiveness of exercise therapy for irritable bowel syndrome: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Efficacy of fermented foods in irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.Frontiers in nutrition · 2024Pooled it
- Pooled it
- The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance.Alimentary pharmacology & therapeutics · 2026Trial
- Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial.BMC primary care · 2026Trial
- Efficacy and Safety of the Enterosorbent Silicolgel in Irritable Bowel Syndrome, IBS-D and IBS-M: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial.Neurogastroenterology and motility · 2025Trial
- Trial
- Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT.Health technology assessment (Winchester, England) · 2024Trial
- Irritable bowel syndrome.Nature reviews. Disease primers · 2026Review
- Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care.Alimentary pharmacology & therapeutics · 2026Article
- Stability of Classification Systems for Irritable Bowel Syndrome.Alimentary pharmacology & therapeutics · 2026Article
- Natural History of Psychological Symptoms in Individuals With Rome IV Irritable Bowel Syndrome and Association With Gastrointestinal Symptom Severity.Neurogastroenterology and motility · 2026Article
- Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom.Alimentary pharmacology & therapeutics · 2026Article
- Gui-Shao San Umbilical Moxibustion for Diarrhea-Predominant Irritable Bowel Syndrome With Liver Depression and Spleen Deficiency Pattern: A Randomized Controlled Trial.Gastroenterology research and practice · 2026Article
- Epidemiology of Meal-Related Abdominal Discomfort or Pain in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Article
- Dietary index for gut microbiota and risk of incident irritable bowel syndrome: a large-scale prospective cohort study.Nutrition journal · 2025Article
- Precision Medicine in Disorders of Gut-Brain Interaction.Gastroenterology & hepatology · 2025Article
- The Impact and Interactions of Race and Gender on Healthcare Use and Spending in Irritable Bowel Syndrome.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025Article
- Could the Therapeutic Effect of Physical Activity on Irritable Bowel Syndrome Be Mediated Through Changes to the Gut Microbiome? A Narrative and Hypothesis Generating Review.Neurogastroenterology and motility · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have demonstrated a substantial economic impact of irritable bowel syndrome (IBS).
aimsTo provide contemporaneous estimates of direct healthcare costs of IBS in the United Kingdom.
methodsWe collected demographic, gastrointestinal and psychological symptoms, quality of life and healthcare usage data from adults with Rome IV or Rome III IBS in the United Kingdom. We calculated the mean annual direct healthcare costs of IBS per person and used contemporaneous IBS prevalence data, together with census data, to estimate annual direct costs of IBS. We also examined predictors of higher costs.
resultsThe mean annual direct cost of IBS per person among 752 individuals with Rome IV IBS was £556.65 (SD £1023.92) and £474.16 (SD £897.86) for 995 individuals with Rome III IBS. We estimate the annual direct healthcare cost of IBS in the United Kingdom is £1.27 billion if the Rome IV criteria are used to define IBS, and £2.07 billion using Rome III. Among individuals with Rome IV IBS, mean annual costs were higher in those with opiate use (£907.90 vs £470.58, p < 0.001), more severe symptoms (p < 0.001 for trend), a shorter duration of IBS (1 year, £1227.14 vs >5 years £501.60, p = 0.002), lower quality of life (p < 0.001 for trend), and higher depression, somatisation and gastrointestinal symptom-specific anxiety scores (P < 0.001 for trend for all).
conclusionWe estimate annual direct healthcare costs of IBS of between £1.3 and £2 billion in the United Kingdom.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.